Masimo Corp

Masimo Corp(MASI)股票分析

$179.950

+0.018 (+0.01%)收盤時

Loading chart…
最高
179.990
開盤
179.950
成交量加權均價
179.96
成交量
3.16M
市值
6.99B
最低
179.950
成交金額
568.70M
企業價值/稅息折舊攤銷前利潤(TTM)
21.69

Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.

AI 分析 of Masimo Corp (MASI)

賣出

Masimo is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is already trading essentially at the acquisition offer level around $180, which leaves very limited upside. Given the pre-market price of 179.95, the best risk/reward is poor for a fresh entry, and the situation is more of a merger-arbitrage hold than a long-term accumulation opportunity. For an impatient investor who does not want to wait for a better entry, this is a sell/no-buy setup rather than a buy.

分析師評級(6)

上檔空間 +4.70%
買進
3 買進
3 持有
0 賣出
目前: 179.95
最低
162.00
平均
188.40
最高
210.00

Raymond James

2026-03-27

目標價

$180

Market Perform

Wells Fargo

2026-03-18

目標價

$180

Equal Weight

Wells Fargo

2025-12-05

目標價

$190

增持

BTIG

2025-12-04

目標價

$200

買進

BofA

2025-11-17

目標價

$162

中性

估值指標

Masimo Corp(MASI)目前預期本益比為 40.82,5 年平均預期本益比為 35.35。

預期本益比

合理
5 年均值 P/E
35.35
目前P/E
40.82
高估
45.14
低估
25.57

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
20.84
目前EV/EBITDA
21.69
高估
26.75
低估
14.92

預期股價營收比

合理
5 年均值 P/S
4.40
目前P/S
5.39
高估
6.36
低估
2.43

Alphio AI 對 MASI 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%MASI

$166.97

情境價格

基

基準

基準 · 50%MASI

$159.11

情境價格

悲

悲觀

悲觀 · 25%MASI

$157.95

情境價格

持有 MASI 的大戶

S

Sofinnova Investments, Inc.

+ 持有MASI

+10.08%

3個月報酬率

A

Alyeska Investment Group, L.P.

+ 持有MASI

+5.63%

3個月報酬率

W

Westfield Capital Management Company, L.P.

+ 持有MASI

-0.98%

3個月報酬率

R

RTW Investments, LP

+ 持有MASI

-7.92%

3個月報酬率

MASI 常見問題 —— 由 Alphio AI 解答

Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Masimo is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is already trading essentially at the acquisition offer level around $180, which leaves very limited upside. Given the pre-market price of 179.95, the best risk/reward is poor for a fresh entry, and the situation is more of a merger-arbitrage hold than a long-term accumulation opportunity. For an impatient investor who does not want to wait for a better entry, this is a sell/no-buy setup rather than a buy.

6 analysts cover MASI: 3 rate it Buy, 3 Hold and 0 Sell. The average price target is 188.40.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易